Literature DB >> 30124911

ADAM8 localizes to extravillous trophoblasts within the maternal-fetal interface and potentiates trophoblast cell line migration through a β1 integrin-mediated mechanism.

H T Le1,2, J Atif2, D L Mara1, B Castellana1,2, J Treissman1,2, J Baltayeva1,2, A G Beristain1,2.   

Abstract

STUDY QUESTION: Does A Disintegrin And Metalloproteinase 8 (ADAM8) control extravillous trophoblast (EVT) differentiation and migration in early human placental development? SUMMARY ANSWER: ADAM8 mRNA preferentially localizes to invasive HLA-G-positive trophoblasts, associates with the acquirement of an EVT phenotype and promotes trophoblast migration through a mechanism requiring β1-integrin. WHAT IS KNOWN ALREADY: Placental establishment in the first trimester of pregnancy requires the differentiation of progenitor trophoblasts into invasive EVTs that produce a diverse repertoire of proteases that facilitate matrix remodeling and activation of signaling pathways important in controlling cell migration. While multiple ADAM proteases, including ADAM8, are highly expressed by invasive trophoblasts, the role of ADAM8 in controlling EVT-related processes is unknown. STUDY DESIGN, SIZE, DURATION: First trimester placental villi and decidua (6-12 weeks' gestation), primary trophoblasts and trophoblastic cell lines (JEG3, JAR, Bewo, HTR8/SVNeo) were used to examine ADAM8 expression, localization and function. All experiments were performed on at least three independent occasions (n = 3). PARTICIPANTS/MATERIALS, SETTING,
METHODS: Placental villi and primary trophoblasts derived from IRB approved first trimester placental (n = 24) and decidual (n = 4) were used to examine ADAM8 localization and expression by in situ RNAScope hybridization, flow cytometry, quantitative PCR and immunoblot analyses. Primary trophoblasts were differentiated into EVT-like cells by plating on fibronectin and were assessed by immunofluorescence microscopy and immunoblot analysis of keratin-7, vimentin, epidermal growth factor receptor (EGFR), HLA-G and ADAM8. ADAM8 function was examined in primary EVTs and trophoblastic cell lines utilizing siRNA-directed silencing and over-expression strategies. Trophoblast migration was assessed using Transwell chambers, cell-matrix binding was tested using fibronectin-adhesion assays, and ADAM8-β1-integrin interactions were determined by immunofluorescence microscopy, co-immunoprecipitation experiments and function-promoting/inhibiting antibodies. MAIN RESULTS AND THE ROLE OF CHANCE: Within first trimester placental tissues, ADAM8 preferentially localized to HLA-G+ trophoblasts residing within anchoring columns and decidua. Functional experiments in primary trophoblasts and trophoblastic cell lines show that ADAM8 promotes trophoblast migration through a mechanism independent of intrinsic protease activity. We show that ADAM8 localizes to peri-nuclear and cell-membrane actin-rich structures during cell-matrix attachment and promotes trophoblast binding to fibronectin matrix. Moreover, ADAM8 potentiates β1-integrin activation and promotes cell migration through a mechanism dependent on β1-integrin function. LIMITATIONS, REASONS FOR CAUTION: The primary limitation of this study was the use of in vitro experiments in examining ADAM8 function, as well as the implementation of immortalized trophoblastic cell lines. Histological localization of ADAM8 within placental and decidual tissue sections was limited to mRNA level analysis. Further, patient information corresponding to tissues obtained by elective terminations was not available. WIDER IMPLICATIONS OF THE
FINDINGS: The novel non-proteolytic pro-migratory role for ADAM8 in controlling trophoblast migration revealed by this study sheds insight into the importance of ADAM8 in EVT biology and placental development. STUDY FUNDING/COMPETING INTEREST(S): This work was supported by grants from the Natural Sciences and Engineering Research Council of Canada (NSERC-Discovery Grant) and the Canadian Institutes of Health Research (CIHR-Open Operating Grant). There are no conflicts or competing interests. TRIAL REGISTRATION NUMBER: NA.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30124911      PMCID: PMC6154767          DOI: 10.1093/molehr/gay034

Source DB:  PubMed          Journal:  Mol Hum Reprod        ISSN: 1360-9947            Impact factor:   4.025


  41 in total

Review 1.  Ectodomain shedding and ADAMs in development.

Authors:  Silvio Weber; Paul Saftig
Journal:  Development       Date:  2012-10       Impact factor: 6.868

2.  Extracellular calumenin suppresses ERK1/2 signaling and cell migration by protecting fibulin-1 from MMP-13-mediated proteolysis.

Authors:  Q Wang; B Shen; L Chen; P Zheng; H Feng; Q Hao; X Liu; L Liu; S Xu; J Chen; J Teng
Journal:  Oncogene       Date:  2014-03-17       Impact factor: 9.867

3.  ADAM28 localizes to HLA-G+ trophoblasts and promotes column cell outgrowth.

Authors:  L C De Luca; H T Le; D L Mara; A G Beristain
Journal:  Placenta       Date:  2017-05-17       Impact factor: 3.481

4.  ADAM8 is a negative regulator of retinal neovascularization and of the growth of heterotopically injected tumor cells in mice.

Authors:  Victor H Guaiquil; Steven Swendeman; Wenhui Zhou; Patricio Guaiquil; Gisela Weskamp; Jörg W Bartsch; Carl P Blobel
Journal:  J Mol Med (Berl)       Date:  2010-01-30       Impact factor: 4.599

5.  N-glycosylation regulates ADAM8 processing and activation.

Authors:  Srimathi Srinivasan; Mathilde Romagnoli; Andrew Bohm; Gail E Sonenshein
Journal:  J Biol Chem       Date:  2014-10-21       Impact factor: 5.157

6.  Differentiation of first trimester cytotrophoblast to extravillous trophoblast involves an epithelial-mesenchymal transition.

Authors:  Sonia DaSilva-Arnold; Joanna L James; Abdulla Al-Khan; Stacy Zamudio; Nicholas P Illsley
Journal:  Placenta       Date:  2015-10-28       Impact factor: 3.481

7.  Identification of novel trophoblast invasion-related genes: heme oxygenase-1 controls motility via peroxisome proliferator-activated receptor gamma.

Authors:  Martin Bilban; Peter Haslinger; Johanna Prast; Florian Klinglmüller; Thomas Woelfel; Sandra Haider; Alexander Sachs; Leo E Otterbein; Gernot Desoye; Ursula Hiden; Oswald Wagner; Martin Knöfler
Journal:  Endocrinology       Date:  2008-10-09       Impact factor: 4.736

8.  Human HLA-G+ extravillous trophoblasts: Immune-activating cells that interact with decidual leukocytes.

Authors:  Tamara Tilburgs; Ângela C Crespo; Anita van der Zwan; Basya Rybalov; Towfique Raj; Barbara Stranger; Lucy Gardner; Ashley Moffett; Jack L Strominger
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-26       Impact factor: 11.205

9.  Notch increases the shedding of HB-EGF by ADAM12 to potentiate invadopodia formation in hypoxia.

Authors:  Begoña Díaz; Angela Yuen; Shinji Iizuka; Shigeki Higashiyama; Sara A Courtneidge
Journal:  J Cell Biol       Date:  2013-04-15       Impact factor: 10.539

10.  ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasis.

Authors:  Mathilde Romagnoli; Nora D Mineva; Michael Polmear; Catharina Conrad; Srimathi Srinivasan; Delphine Loussouarn; Sophie Barillé-Nion; Irene Georgakoudi; Áine Dagg; Enda W McDermott; Michael J Duffy; Patricia M McGowan; Uwe Schlomann; Maddy Parsons; Jörg W Bartsch; Gail E Sonenshein
Journal:  EMBO Mol Med       Date:  2013-12-27       Impact factor: 12.137

View more
  3 in total

1.  ADAM and ADAMTS disintegrin and metalloproteinases as major factors and molecular targets in vascular malfunction and disease.

Authors:  HaiFeng Yang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2022-01-24

2.  Palmitic Acid Impedes Extravillous Trophoblast Activity by Increasing MRP1 Expression and Function.

Authors:  Yunali Ashar; Qiuxu Teng; John N D Wurpel; Zhe-Sheng Chen; Sandra E Reznik
Journal:  Biomolecules       Date:  2022-08-22

3.  Mitochondrial Dynamics in Placenta-Derived Mesenchymal Stem Cells Regulate the Invasion Activity of Trophoblast.

Authors:  Jin Seok; Sujin Jun; Jung Ok Lee; Gi Jin Kim
Journal:  Int J Mol Sci       Date:  2020-11-14       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.